Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatinib

Uz, BurakDolasik, Ilhan2024-08-042024-08-0420161060-02801542-6270https://doi.org/10.1177/1060028015627663https://hdl.handle.net/11616/102629[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor DasatinibLetter5043343352683900610.1177/1060028015627663WOS:000372717400014Q2